Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

“La Gazette du Laboratoire” Features RebrAIn’s Breakthrough in Deep Brain Stimulation

We are pleased to announce that La Gazette du Laboratoire has featured RebrAIn for our revolutionary advancements in neurosurgical targeting for Deep Brain Stimulation (DBS).

The article highlights our collaboration with SATT Aquitaine Science Transfert and the development of our supervised AI-driven platform, OptimDBS, designed to enhance the precision and effectiveness of DBS treatments.

Learn more about how RebrAIn is transforming neurosurgery and improving patient outcomes by reading the full article here, in french.

An English translation by Google is available here.

Our latest public updates

Rebrain x Worldwide Dystonia Research Center

Rebrain x Worldwide Dystonia Research Center

Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...